Overview

* Pacira Q3 revenue up 6% but missed analyst expectations

* Adjusted net income and EBITDA for Q3 beat analyst estimates

* The non-opioid pain therapeutics firm repurchased 2 mln shares for $50 mln in Q3

Outlook

* Pacira updates 2025 revenue guidance to $725 mln-$735 mln, down from $730 mln-$750 mln

* Pacira raises 2025 non-GAAP gross margin guidance to 80%-82% from 78%-80%

* Company expects non-GAAP R&D expenses of $95 mln-$105 mln for 2025

Result Drivers

* EXPAREL VOLUME GROWTH - 9% increase in EXPAREL volume drove revenue growth, partially offset by vial mix shift and discounting from new GPO partnership

* 5x30 STRATEGY - Key milestones in 5x30 growth strategy, including patient enrollment conclusion and exclusive license agreement for AMT-143, advanced growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $179.50 $182.55

Revenue mln mln (6

Analysts

)

Q3 Beat $31.80 $31.44

Adjusted mln mln (5

Net Analysts

Income )

Q3 Net $5.40

Income mln

Q3 Beat $49.40 $46.50

Adjusted mln mln (5

EBITDA Analysts

)

Q3 Cash $246.30

& mln

Investme

nts

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Pacira Biosciences Inc ( PCRX ) is $30.00, about 27.2% above its November 5 closing price of $21.85

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 7 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)